Evidence map›Paper›PMID 42112544›Full record

ArticleActa crystallographica Section B, Structural science, crystal engineering and materials2026

Form (III) of artemisinin: discovery and crystallographic characterization of a new high-pressure polymorph.

Banaz Fetah, Lauren E Connor, Mark R Warren, Cheryl L Doherty, Iain D H Oswald

Abstract read
In one paragraph

Article in Acta crystallographica Section B, Structural science, crystal engineering and materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Banaz FetahStrathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK.ORCID 0009-0003-1953-562X
Lauren E ConnorStrathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK.
Mark R WarrenDiamond Light Source, Harwell Science and Innovation Campus, Chilton, Didcot, OX11 0DE, UK.
Cheryl L DohertyMaterial Science, GlaxoSmithKline, Gunnels Wood Rd, Stevenage, SG1 2NY, UK.
Iain D H OswaldStrathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK.

Funding

Engineering and Physical Sciences Research Council EP/N015401/1Higher Education Funding Council for England HH13054Wellcome Trust 220018
6 · The paper itself

Abstract

Artemisinin (ART) is mainly used for the treatment of malaria and exhibits polymorphism with two known crystalline forms. In this study, the high-pressure behaviour of these two polymorphs was investigated to evaluate their compressibility and identify if any pressure-induced phase transitions occur with a view to assessing the impact of manufacturing pressure on the active pharmaceutical ingredient. Form (I), the orthorhombic polymorph, is found to be the most compressible of the three. Form (II), a triclinic phase, undergoes a phase transition to a new polymorph that is observed at different pressures depending on the pressure-transmitting medium (PTM) used. The transition to form (III) occurs at 0.75 GPa when compressed in petroleum ether, however, this transition is delayed to 2.02 GPa in silicone oil. This highlights the influence of the PTM on the stability of the crystal structure. The newly characterized form (III) shares structural similarities with form (II) but differs in symmetry where a pseudo-2

Indexed as

artemisinincompression-induced transformationdiamond anvil cell (DAC)high pressurepolymorphismsingle crystalXRPD

Identifiers

PMID42112544
PMCPMC13238485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.